Several FLT3 inhibitors have been explored in small clinical trials in pediatric AML patients, and partial or complete responses were reported not only in KMT2A-rearranged ALL (Midostaurin, Lestauritinib), but also in refractory/relapse AML (Sorafenib) (143). The gene discussed is FLT3; the disease is acute myeloid leukemia.